The Plateform

Come discover us !

In the heart of the University Hospital Center of Montpellier

Founded in 2008, the Clinical Proteomics Platform aims to make medical, biological and technical expertise in Clinical Proteomics available to academic and industrial teams.

The Platform is also a major player in clinical research at the University Hospital Center of Montpellier. The latter is in 7th position in the national SIGAPS ranking (number of publications) and is one of the 6 best University Hospitals recognised as “strong researchers”.

PPC, Key Opinion Leader

The PPC, considered as the European Key Opinion Leader in the field of Clinical Proteomics (Shimadzu, Bruker) is managed by Professor Christophe Hirtz, who is assisted by three chemical engineers specialized in mass spectrometry. Since 2011, PPC has participated in the publication of more than 50 international scientific articles. This platform specialized in clinical proteomics is currently the only one in the Occitan region.

Its Goals

The Clinical Mass Spectrometry Platform aims to exploit the latest technological developments in mass spectrometry for the discovery, validation and use of biomarkers in numerous human pathologies (proteins, RNA, DNA, metabolites). Integrated in the Proteome Pole of Montpellier since its creation and labelled IBiSA, its aim is also to make medical, biological and technical expertise in Clinical Proteomics available to academic and industrial teams. The PPC has been ISO 9001 certified since 2014.

For this purpose, several technological approaches based on the use of clinical samples and a high throughput of analyses are available (design and implementation of quantitative and qualitative mass spectrometry methods, identification of proteins in biological matrices, ultra-sensitive and multiplexed immunoassays).

This research is supported by a strong methodological activity mainly in the field of pre-fractionation and pre-analysis as well as an expertise in the field of biomarkers of clinical interest. The PPC also offers training in the platform’s technologies: immunoassays (ELISA), mass spectrometry and proteomics. The PPC is a partner in numerous research projects on Alzheimer’s disease within the framework of national (PHRC Promara, DiatrAl) and international projects (Joint Programming Neurodegenerative Disease, Working Group (WG) of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)). It is also involved in many national projects (IGR Paris, Institut Beaulieu, IRD, INRA). Recently, the PPC has obtained funding for the acquisition of 2 new mass spectrometers in the framework of the CPER 2015-2020 carried by the University of Montpellier.

In 2019, the innovative PRRI PPC-SMART project (2019-2021) led by the University of Montpellier and the CHU, in collaboration with Dr. Alexandre David (IGF) was financed by the Occitanie region with European funds for regional development (ERDF funding) to the tune of 1 million euros.

Clinical Proteomics Platform

Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5

How to find us


Phone: 04 67 33 04 20